Texas-based renal care pharmacy DaVita Rx LLC will pay $63.7 million to resolve federal allegations that include improper billing, the Justice Department said Dec. 14.
The settlement resolves allegations that the Coppell, Texas-based company billed federal health-care programs for prescription medications that were never shipped, or were shipped but subsequently returned, and did not comply with requirements for documentation of proof of delivery, refill requests, or patient consent.
The company touted its cooperation with the government in reaching the settlement. “DaVita is proud that its team discovered and self-disclosed these issues to the federal government in 2015 and 2016 and ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.